Breast cancer patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy. This can be done with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens. The data, published in iCancer Research/i, a journal of the American Association for Cancer Research, indicated that failure of the anti-HER2 antibody trastuzumab to block HER2 from activating ...Thursday, 24 January 2013
In Breast Cancer Patients, Treatment Targeting PI3K may Delay Resistance to Anti-HER2 Therapy
Breast cancer patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy. This can be done with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens. The data, published in iCancer Research/i, a journal of the American Association for Cancer Research, indicated that failure of the anti-HER2 antibody trastuzumab to block HER2 from activating ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment